Michigan bill that would pare back pharma liability shied law moves closer to enactment; Novo Nordisk wants to be a cardiovascular company, too

Taking stock of the drug industry, from the lab to the medicine chest

November 13, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Michigan bill that would pare back pharma liability shield law moves closer to enactment A one-of-a-kind law in Michigan prevents the state and residents from suing pharmaceutical companies over injuries caused by their medicines. By Ed Silverman STAT+ | Novo Nordisk wants to be a cardiovascular company, too, with sights set on inflammation The maker of Wegovy is also developing several treatments specific to heart disease and is acquiring a medication for high blood pressure. By Elaine Chen STAT+ | Eli Lilly's chief scientist on new obesity drug data, gene editing, and a potential new heart drug STAT sat down with Dan Skovronsky to talk about GLP-1s, the new Lp(a) drug, and Eli Lilly's partnership with the gene editing firm Verve. By Matthew Herper APStock STAT+ | In first test for base editing, Verve's one-time treatment lowers cholesterol levels in patients The results are preliminary but signal the potential for gene-editing treatments to benefit people with a condition known as HeFH. By Adam Feuerstein STAT+ | Anthos stroke drug appears safer than common blood thinner in mid-stage trial In a mid-stage trial, abelacimab cut the overall risk of bleeding by 67% compared to rivaroxaban, the blood thinner sold as Xarelto. By Elaine Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser